Antibody

34개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved34 programs
AntibodyLimited DatastaleMonopteros Therapeutics Inc.Phase 1

pembrolizumab (Keytruda, MPT-0118 + pembrolizumab)

Solid Tumor, Adult; Advanced Solid Tumor · FRα

#FR#Antibody#Phase1#monoclonal-antibody#SolidTumor+3
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab (Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RefractoryMetastaticColorectalCa+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAbGenomics B.V Taiwan BranchPhase 2

Neihulizumab Treatment (Neihulizumab Treatment)

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation · FRα

#FR#Antibody#Phase2#monoclonal-antibody#Steroid-refractoryaGvHDSubsequen+1
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#FollicularLymphoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleSCRI Development Innovations, L…Phase 1

PTK787/ZK222584 and Bevacizumab (PTK787/ZK222584 and Bevacizumab)

Refractory Malignancy; Advanced Malignancies · FRα

#FR#Antibody#Phase1#monoclonal-antibody#RefractoryMalignancy+2
Trials 1Status Active
AntibodyLimited DatastaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedRefractoryMultipleMyelom+1
Trials 1Status Recruiting
AntibodyLimited DatastaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NSCLC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RefractoryMetastaticColorectalCa+1
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#ClinicalStageIVCutaneousMelanoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NoncontiguousStageIISmallLymphoc+2
Trials 1Status Active
AntibodyLimited DatastaleShahid Beheshti University of M…Phase 3

injection of bevacizumab (injection of bevacizumab)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryDiabeticMacularEdema+1
Trials 1Status Active
AntibodyLimited DatastaleShahid Beheshti University of M…Phase 3

injection of bevacizumab and erythropoietin (injection of bevacizumab and erythropoietin)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryDiabeticMacularEdema+1
Trials 1Status Active

2 / 2 pages

← PreviousNext →